 Phase 1 study to evaluate ON 123300 in advanced cancer patients including HR HER 2- metastatic breast cancer patients resistant to approved CDK 46 inhibitors Phase 1 study to evaluate ON 123300 in advanced cancer patients including HR HER 2- metastatic breast cancer patients resistant to approved CDK 46 inhibitors 